Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +41.87%
#2 0G 0G +29.33%
#3 SAFEcoin SAFEcoin +22.40%
#4 VVS Finance VVS Finance +20.47%
#5 Seeker Seeker +20.05%
#6 Zora Zora +19.92%
#7 Full Moon Full Moon +17.70%
#8 Concordium Concordium +17.06%
#9 Notcoin Notcoin +15.26%
#10 Axelar Axelar +15.23%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Classement en actions #12751
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Prix de l'action
$22.26
Dernière synchronisation: 2024-03-22
Capitalisation boursière
$553.40M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Graphite Bio, Inc. (GRPH)

Catégorie

Healthcare
Bénéfices pour Graphite Bio, Inc. (GRPH)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Graphite Bio, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Graphite Bio, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH